pSNAP: Proteome-wide analysis of elongating nascent polypeptide chains

Junki Uchiyama¹, Rohini Roy^{2,3}, Dan Ohtan Wang^{2,4,5}, Chiaki Yoshino¹, Yuichiro Mishima⁶, Yasushi Ishihama^{1,7*}, Koshi Imami^{1,8*}

¹ Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501, Japan

² Institute for Integrated Cell-Material Sciences (iCeMS), Kyoto University, Kyoto, 606-8501, Japan

³ Graduate School of Biostudies, Kyoto University, Kyoto, 606-8501, Japan

⁴ Wuya College of Innovation, Shenyang Pharmaceutical University, 110001, China

⁵ Center for Biosystems Dynamics Research, RIKEN, Kobe, Hyogo 650-0047, Japan

⁶ Faculty of Life Sciences, Kyoto Sangyo University, Kita-ku, Kyoto 603-8555, Japan

⁷ Laboratory of Clinical and Analytical Chemistry, National Institute of Biomedical Innovation, Health and Nutrition, Ibaraki, Osaka, 567-0085, Japan

⁸ PRESTO, Japan Science and Technology Agency (JST), Chiyoda-ku, Tokyo, 102-0075, Japan

*Corresponding authors:

Koshi Imami

Department of Molecular and Cellular BioAnalysis,

Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501, Japan

Tel.: +81-75-753-4565

Fax.: +81-75-753-4601

email: imami.koshi.3z@kyoto-u.ac.jp

Yasushi Ishihama

Department of Molecular and Cellular BioAnalysis,

Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501, Japan

Tel.: +81-75-753-4555

Fax.: +81-75-753-4601

email: yishiham@pharm.kyoto-u.ac.jp

Summary

Cellular global translation is often measured using ribosome profiling or quantitative mass spectrometry, but these methods do not provide direct information at the level of elongating nascent polypeptide chains (NPCs) and associated co-translational events. Here we describe pSNAP, a method for proteome-wide profiling of NPCs by affinity enrichment of puromycin- and stable isotope-labeled polypeptides. pSNAP does not require ribosome purification and/or chemical reaction, and captures *bona fide* NPCs that characteristically exhibit protein N-terminus-biased positions. We applied pSNAP to evaluate the effect of silmitasertib, a potential molecular therapy for cancer and COVID-19 patients, and revealed acute translational repression through casein kinase II and mTOR pathways. We also characterized modifications on NPCs and demonstrated that the combination of different types of modifications, such as acetylation and phosphorylation in the N-terminal region of histone H1.5, can modulate interactions with ribosome-associated factors. Thus, pSNAP provides a framework for dissecting co-translational regulations on a proteome-wide scale.

Introduction

Co-translational regulation, such as modifications of nascent polypeptide chains (NPCs) during translation, drives many aspects of cellular proteostasis, including protein folding, processing, subcellular targeting, and translational control (Collart and Weiss, 2020; Schwarz and Beck, 2019). Therefore, monitoring co-translational events at the NPC level is crucial for understanding cellular proteome dynamics at the moment a peptide is born.

Current approaches for systematically profiling the newly synthesized proteome are mainly based on the capture of proteins metabolically labeled with stable isotope-labeled (SILAC) amino acids (Doherty et al., 2009; Klann et al., 2020; Schwanhäusser et al., 2009) or bioorthogonal amino acids such as azidohomoalanine (Dieterich et al., 2006; Eichelbaum et al., 2012; McShane et al., 2016). These methods allow us to profile mainly fully translated products (Eichelbaum et al., 2012; McShane et al., 2016), but cannot enrich NPCs actively being elongated by ribosomes in action. In contrast, puromycin is an aminoacylated tRNA analog that can be incorporated at the C-termini of elongating NPCs (Aviner, 2020). Hence, puromycin labeling has been extensively used to monitor protein synthesis in many applications, including imaging and immunoblotting, and in various systems ranging from cell-free translation to cultured cells and whole animals (Aviner, 2020). However, the utility of puromycin or its derivatives for proteome-wide analysis of NPCs has been limited due to the need for complicated procedures, including ribosome purification by ultracentrifugation (Aviner et al., 2013) and/or chemical labeling (Forester et al., 2018; Huang et al., 2021; Tong et al., 2020; Uchiyama et al., 2020) prior to affinity purification of NPCs. Furthermore, reliable detection of NPCs is often hampered by non-specific binding of high background pre-existing proteins to beads or resin during affinity purification (Eichelbaum et al., 2012; Howden et al., 2013; Mellacheruvu et al., 2013).

To overcome these limitations, we have developed a method that combines quantitative proteomics and dual pulse labeling with puromycin and SILAC amino acids, termed Puromycin- and SILAC labeling-based NAScent Polypeptidome profiling (pSNAP). We demonstrate the broad utility of the method by applying it to both HeLa cells and primary cells to characterize rapid translational changes as well as co-translational modifications such as protein N-terminal acetylation.

Results and Discussion

pSNAP enables global profiling of nascent polypeptide chains

We reasoned that NPCs incorporating puromycin could be immunoprecipitated with an anti-puromycin antibody (**Fig. 1a**), thereby allowing for proteome-wide analysis of NPCs by means of liquid chromatography-tandem mass spectrometry (LC/MS/MS). We first confirmed that puromycin incorporation into proteins was translation-dependent (**Supplementary Fig. 1a**) and that no marked degradation of the puromycin-labeled proteins occurred during 2 hr treatment of HeLa cells with 10 μ M puromycin (**Supplementary Fig. 1b**). We then tested a monoclonal antibody against puromycin (clone 12D10) and found that puromycylated proteins could be effectively immunoprecipitated when appropriate amounts of the antibody and input protein were used (**Supplementary Fig. 1c**). Based on these results, we used 15 μ g antibodies per 250 μ g protein input for subsequent immunoprecipitation (IP) experiments.

We next sought to profile individual NPCs with LC/MS/MS. For proof-of-concept, HeLa cells were pulse-labeled with a combination of puromycin and 'heavy (H)' amino acids (Arg'10' and Lys'8') for 2 hr (**Fig. 1b**). As a control, cells were treated with only 'medium-heavy (M)' amino acids (Arg'4' and Lys'4') and puromycin was omitted. The use of 'M' and 'H' labeling enabled us to distinguish *bona fide* NPCs (H-labeled) from non-specific proteins [light (L)- or M-labeled]. As expected, H-labeled proteins were highly enriched in the IP sample (**Fig. 1c top**) while pre-existing proteins were predominantly observed in the input (**Fig. 1c bottom**). Overall, we observed high H/M ratios (≥ 2) for 70% of 2,619 quantified proteins with good reproducibility (**Fig. 1d** and **Supplementary Table 1**), demonstrating that pSNAP can profile thousands of NPCs. In contrast, we observed low H/L ratios (< 1) for 62 % of the quantified proteins (**Supplementary Fig. 1d**) due to the high background resulting from non-specific binding of pre-existing proteins (L) to beads. These results highlight the importance of pulse labeling with SILAC amino acids to differentiate NPCs and pre-existing proteins.

Proteins captured by pSNAP exhibit a signature of elongating nascent polypeptides

Ribosomes elongate NPCs from their amino (N-) terminal end to their carboxy (C-) terminal end (**Fig. 1e top**). In line with this directionality, the positions of peptides with $H/M \geq 2$ clearly showed a bias towards the N-termini of the corresponding proteins (**Fig. 1e bottom**), further supporting

the enrichment of elongating NPCs. Notably, such a trend was not observed for less enriched peptides (i.e., H/M<2) or input cell lysates (**Figure 1e bottom**). In addition to HeLa cells, we applied pSNAP to mouse primary cortical cultures, which contains a mixture of brain cell types but are highly enriched for neurons (**Supplementary Fig. 2a**). pSNAP revealed the strong enrichment of peptides near the N-termini of proteins. (**Supplementary Figs. 2b, c**) and achieved highly sensitive detection of NPCs, including neuronal markers; NCAM1, FOXG1, and DCX, supporting the validity of the results in HeLa cells (**Supplementary Table 2**). We also quantified the differential NPC profiles between 5 and 14 days in vitro (DIV) (**Supplementary Figs. 2d-f** and **Supplementary Table 3**), which overall reflected the known proteome dynamics during the neuronal development in vitro (Frese et al., 2017). For example, nascent proteins related to 'synaptic vesicle cycle' were overrepresented in DIV14 (**Supplementary Fig. 2f**), consistent with the occurrence of synapse formation and maintenance after development. Collectively, these results indicate that pSNAP captures genuine NPCs and enables quantitative nascent proteome analysis.

Quantifying translational responses induced by a kinase inhibition

The ability to capture and quantify NPCs proteome-wide with high accuracy enables quantitative measurements of acute translational changes that allow cells to respond to specific stimuli. To illustrate this, we next applied pSNAP to characterize the global impact of a kinase inhibitor on cellular translation. We focused on casein kinase 2 (CK2) as it is ubiquitously expressed in all cells, and has been implicated in translational control through phosphorylation of specific eukaryotic initiation factors (eIFs) (Gandin et al., 2016; Lamper et al., 2020). However, the protein targets of translational regulation by CK2 remain unknown. Therefore, HeLa cells were pre-incubated with either DMSO or a specific CK2 inhibitor silmitasertib (also known as CX4945) (Siddiqui-Jain et al., 2010) for 10 min (**Fig. 2a**), and then pulse-labeled with puromycin and SILAC amino acids for 2 hr in the presence of DMSO or silmitasertib, and processed as illustrated in **Fig. 1b**. H/M ratios in MS spectra represent the difference in production of NPCs between the two conditions (silmitasertib and DMSO treatments). We first confirmed that NPCs could be enriched: H- and M-labeled peptides both exhibited the trend of protein N-terminus-biased positions (**Supplementary Fig. 3a**).

To understand the gene expression networks at the NPC level, we first asked whether in vitro CK2 substrates (Sugiyama et al., 2019) might be regulated translationally but found no evidence

for that (**Fig. 2b**). On the one hand, we found that CK2 inhibition led to marked repression of NPCs with a 5' terminal oligopyrimidine (TOP) motif in their mRNAs ($p = 5.7e-16$), encoding for components of the translational machinery (**Fig. 2b** and **Supplementary Fig. 3b**). TOP mRNAs are well-known targets that are subject to selective translation through mTORC1 (Hsieh et al., 2012; Thoreen et al., 2012). Hence, CK2 may regulate the translation of TOP mRNAs in concert with mTORC1, in line with a previous report that CK2 enhances mTORC1 activity (Gandin et al., 2016). In addition, pSNAP revealed that the translation of specific subsets of proteins (e.g., RCOR1, RAE1, and RNPS1) was down-regulated (**Supplementary Table 4**). Thus, our analysis uncovered acute translational responses to silmitasertib via the CK2 and mTOR pathways, which may contribute to further understanding of the mechanism of action of silmitasertib, a promising molecular therapy for several types of cancers (phase II) (Siddiqui-Jain et al., 2010) as well as SARS-CoV-2 infection (Bouhaddou et al., 2020).

Profiling modifications on nascent proteins

The present method not only enables the global profiling of NPCs, but also highlights the co-translationally regulated modifications of NPCs. Conventional proteomic approaches cannot resolve post- and co-translational modifications, and so the distribution of the two types of modifications within a protein goes undetected; yet the timing of modifications can be important for protein processing (Aksnes et al., 2019; Varland et al., 2015) such as folding (Keshwani et al., 2012; Kii et al., 2016). By detecting NPCs with their modification states, pSNAP can be particularly useful in revealing co-translational modifications. In the silmitasertib treatment experiment (**Fig. 2a**), we found that CK2 inhibition led to decreased phosphorylation levels on nascent forms of known CK2 substrates, such as G3BP1 pS149 (Reineke et al., 2017), HSP90AA1 pS231, and HSP90AB1 pS226, pS255 (Mollapour and Neckers, 2012), while no marked change was observed at the NPC level (**Fig. 2c** and **Supplementary Table 4**). Hence, CK2 may act in close proximity to the ribosome to co-translationally phosphorylate nascent proteins, possibly regulating protein stability through phosphorylation of newly made proteins, as observed for XRCC1 (Parsons et al., 2010) and CFTR (Pankow et al., 2019).

Protein N-terminal (Nt) acetylation is one well-studied 'co-translational' modification (Aksnes et al., 2019; Yeom et al., 2017); however, recent studies have revealed 'post-translational' Nt-acetylation on many transmembrane proteins and actin (Yeom et al., 2017). While earlier N-terminomics studies identified thousands of protein Nt-acetylation sites (Choudhary et al., 2014;

Lai et al., 2015; Yeom et al., 2017), it remains unclear whether these sites are co- or post-translationally modified. We thus sought to apply pSNAP to pinpoint co-translational Nt-acetylation sites with high accuracy. For this purpose, HeLa cells were treated with either CHX or DMSO for 2 hr in the presence of puromycin and corresponding SILAC amino acid pairs. By combining pSNAP with low pH strong cation exchange (SCX) chromatography (Helbig et al., 2010), we enriched Nt-acetylated peptides that were eluted in the flow-through fraction and early in SCX fractionation due to the loss of positive charge at their N-terminal ends (**Fig. 3a**). We confirmed that the NPCs could be enriched (**Supplementary Figs. 4a, b** and **Supplementary Table 5**) and identified 298 unique protein Nt-acetylated sites that exhibited H/M (DMSO/CHX) ≥ 2 in at least one of the three replicates. Of note, beta-actin's Nt-acetylation showed H/M<1 in all replicates, indicating that it occurs post-translationally, in agreement with a previous report (Drazic et al., 2018). To better understand acceptor sites for co-translational Nt-acetylation, we focused on amino acids at the second residue [next to the initiator methionine (iMet)] (**Fig. 3b**). In accordance with the substrate specificity of major N-terminal acetyltransferases (Aksnes et al., 2019; Yeom et al., 2017), we observed a high prevalence of alanine and serine for Nt-acetylated NPCs whose iMet was cleaved ($p<0.01$, v.s. amino acid frequency at the second residue of the human proteome), while the acidic amino acids (aspartic acid and glutamic acid) and phenylalanine were overrepresented in the iMet-retained and Nt-acetylated NPCs ($p<0.01$) (**Fig. 3b**). Hence, these specific amino acids at the N-termini might be key determinants in regulating a protein's life and function at birth (Timms et al., 2019).

Protein N-terminal modifications on a nascent protein can modulate binding partners

Protein N-termini are hotspots for modifications during translation and thus can regulate co-translational events such as folding and degradation through interactions with proteins (Collart and Weiss, 2020). We next sought to discover cross-talk between protein Nt-acetylation and other modifications on NPCs as the combination of different types of modifications confers additional specificity and combinatorial logic to protein interactions. We searched our dataset focusing on phosphorylation, which can function as a versatile switch to modulate protein interactions. We identified 134 phosphorylated peptides in the Nt-acetylation-enriched samples. Among them, we focused on phosphorylation at Ser19 of histone H1.5 (H1.5) co-occurring with protein Nt-acetylation within the same peptide (**Fig. 3c**). Peptide-level quantification of H-labeled peptides indicated that the Nt-acetylated form is a major nascent proteoform of H1.5 (**Fig. 3d**). Such highly

stoichiometric patterns of nascent Nt-acetylation were also seen for the 13 sites whose Nt-acetylated and its counterpart (unmodified) peptides were both quantified (**Fig. 3e**), in marked contrast to the very low (median 0.02%) stoichiometry of lysine acetylation in HeLa cells (Hansen et al., 2019).

To understand the role of the nascent modifications and their impacts on protein interactions, we performed peptide-based pulldown experiments on HeLa cell lysate using three distinct peptide probes that mimic 1) Nt-unmodified, 2) Nt-acetylated, or 3) Nt-acetylated and phosphorylated forms of H1.5 (**Fig. 3f**). The peptide-based screen revealed proteins that differentially interacted with the specific peptide probes (**Fig. 3g** and **Supplementary Table 6**). One prominent example is a ubiquitin E3 ligase complex (KLHL13, KLHL22, CUL3, BIRC6) that showed a robust interaction with the unmodified peptides (**Fig. 3g** left). Thus, Nt-unmodified H1.5 is likely to be degraded through the ubiquitin-proteasome system, which may explain why the Nt-unmodified H1.5 was markedly less abundant than the acetylated forms in HeLa cells (**Fig. 3d**). Accordingly, protein Nt-acetylation of H1.3 is protective against protein degradation, in line with the idea that Nt-acetylated mitochondrial proteins bearing inhibitor of apoptosis binding (IAP) motifs are shielded from the IAP family of E3 ubiquitin ligases (Mueller et al., 2021). Interestingly, the Nt-acetylated and phosphorylated version of the peptide preferentially bound a co-translational quality control factor PELOTA while disfavoring the interaction with a molecular chaperone HSPA6 (**Fig. 3g** right). PELOTA was shown to promote the dissociation of stalled ribosomes and the release of intact peptidyl-tRNA for ribosome recycling (Pisareva et al., 2011); Thus, the nascent H1.5 phosphorylation in the N-terminal region may represent an additional 'modification code' to recruit PELOTA and to repel HSPA6 as a surveillance mechanism for aberrant nascent H1.5. In summary, pSNAP enables us to uncover modifications on NPCs that may represent a new layer of translational control, i.e., one shaped by nascent protein modifications.

Limitations of the method

While puromycin or its analogue has been used to analyze protein synthesis in many cell lines and model systems (Aviner, 2020), it may also cause a secondary effect on cellular translation (Marciano et al., 2018). In this study, we therefore used a relatively low concentration of puromycin that did not affect cell viability or degradation of puromycylated proteins at least in HeLa cells, but further investigations would be required to characterize the mode of action of puromycin in detail. We demonstrated that pSNAP can be readily applicable to a cell line and primary-cultured cells,

though further development will be needed for its application to in vivo systems. For example, the direct enrichment and proteomic analysis of puromycylated peptides digested from NPCs provides a signature of genuine NPCs, and would not require pulse SILAC labeling, which is not generally feasible in animals.

Conclusions

The pSNAP approach presented here offers multiple advantages over currently available methods for capturing NPCs with co-translational modifications, a hidden layer in understanding translational regulations in cell biology, but are inaccessible by conventional ribosome profiling or proteomic approaches. The advantage of pSNAP lies in the use of dual pulse labeling. The incorporation of puromycin facilitates the enrichment of NPCs from a complex background, and in turn, the use of pulsed SILAC enables both protein quantification and the ability to discriminate nascent from pre-existing proteins. Moreover, the experimental workflow is simple in contrast to existing methods that involve ribosome purification using ultracentrifugation(Aviner et al., 2013) and/or chemical labeling steps (Forester et al., 2018; Huang et al., 2021; Tong et al., 2020; Uchiyama et al., 2020). In addition, the method does not require special puromycin derivatives such as biotin-puromycin (Aviner et al., 2013)or clickable puromycin(Forester et al., 2018; Huang et al., 2021; Tong et al., 2020; Uchiyama et al., 2020). Our results show that pSNAP can quantify changes in NPC levels in response to environmental cues, and is useful for characterizing co-translational modifications. It might also be employed in combination with biochemical enrichment techniques for specific modified forms of peptides/proteins. In addition, this method could be applied to identify the NPC interactome during translation since some proteins appear to form homo- (Bertolini et al., 2021) or hetero- (Kamenova et al., 2019) complexes in a co-translational manner.

Figure legends

Fig. 1 Profiling nascent polypeptide chains by pSNAP.

a, Principle of the enrichment of NPCs with the pSNAP. **b**, Schematic representation of pSNAP workflow. HeLa cells are pulse labeled for 2 hr with a combination of 10 μ M puromycin and heavy amino acids or with only medium-heavy amino acids. After IP of NPCs with anti-puromycin antibodies, NPCs are eluted with 0.15% TFA and digested into tryptic peptides. The resulting peptide sample is analyzed by LC/MS/MS. Heavy-to-medium (H/M) ratios represent the degree of enrichment of NPCs. **c**, Exemplary MS spectra for AAALEFLNR (STIP1) obtained with (top) and without (bottom) enrichment. The isotope clusters of the L, M, and H peaks correspond to non-specific proteins from the pre-existing proteome pool and from the 'medium'-labeled proteins and 'heavy'-labeled NPCs, respectively. **d**, Multi-scatter plots of $\log_2$ H/M ratios from three independent experiments. **e**, pSNAP can enrich NPCs. (top) The ribosome elongates an NPC from its N-terminal end to the C-terminal end. Thus, positions of NPC-derived tryptic peptides are biased towards the N-termini of proteins. (bottom) Relative starting positions of identified peptides within proteins. The bars represent averaged values from three independent experiments.

Fig. 2 Quantitative analysis of translational responses and co-translational phosphorylation.

a, Experimental design for global analysis of translational changes induced by a CK2 inhibitor silmitasertib (10 μ M). **b**, A histogram of $\log_2$ fold changes [H/M (silmitasertib/DMSO) ratios] of protein synthesis induced by silmitasertib. Averaged H/M ratios based on proteins quantified in at least two of the three replicates are shown. Results from individual replicates are shown in **Supplementary Fig. 3b**. A subset of proteins whose mRNAs contain a TOP motif is shown in dark blue. CK2 substrates determined by an in vitro kinase reaction (Sugiyama et al., 2019) are shown in orange. All quantified proteins are shown in black. The dashed lines indicate median values of the three groups (all, TOP motif, and CK2 substrates) The p-value was computed using the two-sided Wilcoxon rank-sum test. **c**, Change of NPC and phosphorylation levels due to silmitasertib treatment versus DMSO treatment. The indicated phosphorylation sites of G3BP1, HSP90AA1 and HSP90AB1 are known CK2 substrates. Levels of the NPCs were quantified from NPC-derived unphosphorylated peptides. The bars represent averaged values from two or three replicates.

Fig. 3 Characterization of protein Nt-acetylation and phosphorylation on nascent proteins

a, Enrichment of Nt-acetylated peptides with SCX-based fractionation. The percentage of the number of protein Nt-acetylated peptides in all peptides identified in individual fractions is shown. The bars represent averaged values from three replicates. **b**, The amino acid frequency at the second residue next to iMet of acetylated protein N-termini based on the absence (pink) or presence (light green) of iMet. Only nascent proteins that showed H/M>2 in at least one of the three replicates were considered. For comparison, the human proteome from the SwissProt protein database is shown. The p-value was computed using Fisher's exact test. **c**, Representative MS/MS spectra of Ac-SETAPAETATPAPVEK (left) and Ac-SETAPAETATPAPVEKpSPAK (right) from histone H1.5. The insets show representative MS spectra of corresponding peptides and demonstrate that the protein Nt-acetylation and adjacent phosphorylation occurred on nascent H1.5. **d**, The comparison of H-labeled peptide intensities from Nt-acetylated (red), Nt-acetylated and phosphorylated (orange), and Nt-unmodified (grey) forms. **e**, Stoichiometry (%) of protein Nt-acetylation estimated based on intensities of H-labeled peptides from Nt-acetylated and counterpart (unmodified) forms. The bars represent averaged values from two or three replicates. **f**, Experimental design for peptide-pulldown assays using three different peptide probes. Nt-unmodified, Nt-acetylated, or Nt-acetylated and phosphorylated biotinylated peptides corresponding to amino acid residues from 2 to 22 (SETAPAETATPAPVEKSPAKK) of H1.5 were conjugated to streptavidin agarose resins. Beads were incubated with HeLa cell lysate, and eluted for LC/MS/MS analysis. **g**, Volcano plots from the pulldown assays of Nt-free vs Nt-acetylated peptides (left) and Nt-acetylated vs Nt-acetylated and phosphorylated peptides (right) are shown.

Supplementary Fig. 1 Assessment of puromycin labeling and immunoprecipitation of puromycylated proteins.

a, Puromycin labeling of proteins is translation-dependent. Western blots (left) and Ponceau staining (right) of whole-cell lysates of HeLa cells treated with 10 μ M puromycin for 2 hr, or 10 μ M puromycin and CHX for 2 hr, or neither. **b**, Abundance of puromycylated proteins was not altered in the presence of a proteasome inhibitor (10 μ M MG132 or 1 μ M bortezomib) over 2 hr treatment. Western blotting was performed with anti-puromycin antibody (left), anti-ubiquitin antibody (middle), and Ponceau staining (right). This result indicates that puromycylated NPCs were not significantly degraded via the ubiquitin-proteasome system in this time frame, while levels of ubiquitinated total cellular proteins were increased in the presence of proteasome inhibitors. **c**, Puromycylated proteins can be immunoprecipitated. Immunoprecipitation (IP) was performed for

different protein inputs (50, 100, 250, and 500 μ g) with a fixed amount of 15 μ g anti-puromycin antibody. The proteins eluted with 0.15% TFA and the remaining supernatant in a post-IP sample were analyzed by means of immunoblotting with the anti-puromycin antibody. 50-250 μ g protein inputs were found to be suitable for immunoprecipitation with 15 μ g anti-puromycin antibodies. **d**, Multi-scatter plots of $\log_2$ H/L ratios from three independent experiments of puromycin (H) and no-puromycin (L) treatments.

Supplementary Fig. 2 Application of pSNAP to mouse primary cortex culture.

a, Schematic representation of the pSNAP workflow. Mouse primary cortical neurons are pulse labeled for 2 hr with a combination of 10 μ M puromycin and heavy amino acids or only medium-heavy amino acids. After IP of NPCs with anti-puromycin antibodies, NPCs are eluted with 0.15% TFA and digested into tryptic peptides. The resulting peptide sample is analyzed by LC/MS/MS. **b**, Multi-scatter plots of $\log_2$ H/M ratios from three independent experiments using mouse primary neurons. **c**, pSNAP can enrich NPCs from primary neurons. Relative starting positions of identified peptides within proteins for enriched (left) or input (right) samples. The bars represent averaged values from three independent experiments. **d**, Experimental design for the differential nascent proteome profiling of the mouse primary cultures between DIV 5 and 14. **e**, A volcano plot showing differential NPC levels between DIV 5 and 14. $\log_2$ FC (H/M: DIV14/DIV5) and p-values are computed from three biological replicates (see method). **f**, Gene ontology enrichment analyses for the significantly regulated NPCs ($\log_2$ FC>0.5 and p<0.05).

Supplementary Fig. 3 Quantitative analysis of translational changes associated with CX-4945 treatment.

a, pSNAP can enrich NPCs from HeLa cells treated with DMSO or CX-4945. Relative starting positions of identified peptides (only M- or H-labeled) within proteins for NPC-enriched samples. The bars represent averaged values from three independent experiments. **b**, Histogram of $\log_2$ FCs [H/M (silmittasertib/DMSO) ratios] of protein synthesis induced by silmittasertib. Results from individual replicates are shown. A subset of proteins whose mRNAs contain a TOP motif is shown in light blue. All quantified proteins are shown in pink. The p values were computed using two-sided Wilcoxon rank-sum test.

Supplementary Fig. 4 Quantitative analysis of nascent protein N-terminal acetylation.

a, Multi-scatter plots of $\log_2$ H/M ratios from three independent experiments using HeLa cells treated with DMSO or CHX. **b**, pSNAP can enrich NPCs. Relative starting positions of identified

peptides within proteins for enriched (left) or input (right) samples. The bars represent averaged values from three independent experiments.

Acknowledgements

We are very grateful to Erik McShane (Harvard Medical School), Matthew L Kraushar (Charité-Universitätsmedizin Berlin), and Tatsuya Niwa (Tokyo Institute of Technology) for critical reading of the manuscript. We thank the members of the Department of Molecular & Cellular BioAnalysis and the Department of Proteomics, Drug Discovery for fruitful discussion. KI thanks the Samuro Kakiuchi Memorial Research Award for Young Scientists for supporting this study. This work was supported by JSPS Grant-in-Aid for Scientific Research (Grant Numbers JP18K14674, JP20H03241, JP20H04844 to KI and 17H05667 to YI), JST PRESTO (JPMJPR18H2), the Takeda Science Foundation to KI, AMED (18dm0307023h) to DOW, JST Strategic Basic Research Program CREST (18070870), and AMED Advanced Research and Development Programs for Medical Innovation CREST (18068699) to YI.

Author contributions

Conceptualization & Methodology, J.U., Y.I., and K.I.; Investigation, J.U., R.R., Y.M., D.O.W., Y.C, Y. I., and K.I.; Resources, D.O.W., Y.M., Y.I., and K.I.; Writing - Original Draft, K.I.; Writing - Review & Editing, J.O., R.R., Y.M, D.O.W., Y.I., Supervision, Y.I. and K.I..

Competing interests

The authors declare no competing financial interest.

Supplementary information

Supplementary Figs. 1–4

Supplementary Table 1 (related to Fig. 1): LC/MS/MS proteomic analysis of NPCs from HeLa cells treated with (H) or without (M) puromycin.

Supplementary Table 2 (related to Supplementary Fig. 2b): LC/MS/MS proteomic analysis of NPCs from mouse primary cells treated with (H) or without (M) puromycin.

Supplementary Table 3 (related to Supplementary Fig. 2b): LC/MS/MS differential proteomic analysis of NPCs from mouse primary cells between DIV5 (M) and DIV14 (H). Statistical comparisons were made using two-sided Student's t-test.

Supplementary Table 4 (related to Fig. 2b): LC/MS/MS differential proteomic analysis of NPCs from HeLa cells treated with DMSO (M) or silmitasertib (H). Statistical comparisons were made using two-sided Wilcoxon rank-sum test.

Supplementary Table 5 (related to Fig. 3b): LC/MS/MS differential proteomic analysis of NPCs from HeLa cells treated with CHX (M) or DMSO (H). Unique protein Nt-acetylated sites that exhibit $H/M \geq 2$ are also shown.

Supplementary Table 6 (related to Fig. 3g): LC/MS/MS differential proteomic analysis of peptide-based pulldown experiments on HeLa cells. Statistical comparisons were made using two-sided Student's t-test.

References

- Aksnes, H., Ree, R., and Arnesen, T. (2019). Co-translational, Post-translational, and Non-catalytic Roles of N-Terminal Acetyltransferases. *Mol. Cell* 73, 1097–1114.
- Aviner, R. (2020). The science of puromycin: From studies of ribosome function to applications in biotechnology. *Comput. Struct. Biotechnol. J.* 18, 1074–1083.
- Aviner, R., Geiger, T., and Elroy-Stein, O. (2013). Novel proteomic approach (PUNCH-P) reveals cell cycle-specific fluctuations in mRNA translation. *Genes Dev.* 27, 1834–1844.
- Bertolini, M., Fenzl, K., Kats, I., Wruck, F., Tippmann, F., Schmitt, J., Auburger, J.J., Tans, S., Bukau, B., and Kramer, G. (2021). Interactions between nascent proteins translated by adjacent ribosomes drive homomer assembly. *Science* 371, 57–64.
- Bouhaddou, M., Memon, D., Meyer, B., White, K.M., Rezeli, V.V., Correa Marrero, M., Polacco, B.J., Melnyk, J.E., Ulferts, S., Kaake, R.M., et al. (2020). The Global Phosphorylation Landscape of SARS-CoV-2 Infection. *Cell* 182, 685–712.e19.
- Choudhary, C., Weinert, B.T., Nishida, Y., Verdin, E., and Mann, M. (2014). The growing landscape of lysine acetylation links metabolism and cell signalling. *Nat. Rev. Mol. Cell Biol.* 15, 536–550.
- Collart, M.A., and Weiss, B. (2020). Ribosome pausing, a dangerous necessity for co-translational events. *Nucleic Acids Res.* 48, 1043–1055.
- Dieterich, D.C., Link, A.J., Graumann, J., Tirrell, D.A., and Schuman, E.M. (2006). Selective identification of newly synthesized proteins in mammalian cells using bioorthogonal noncanonical amino acid tagging (BONCAT). *Proc. Natl. Acad. Sci. U. S. A.* 103, 9482–9487.
- Doherty, M.K., Hammond, D.E., Clague, M.J., Gaskell, S.J., and Beynon, R.J. (2009). Turnover of the human proteome: determination of protein intracellular stability by dynamic SILAC. *J. Proteome Res.* 8, 104–112.

481 Drazic, A., Aksnes, H., Marie, M., Boczkowska, M., Varland, S., Timmerman, E., Foy, H.,
482 Glomnes, N., Rebowski, G., Impens, F., et al. (2018). NAA80 is actin's N-terminal
483 acetyltransferase and regulates cytoskeleton assembly and cell motility. *Proc. Natl. Acad. Sci.*
484 *U. S. A.* **115**, 4399–4404.

485 Eichelbaum, K., Winter, M., Berriel Diaz, M., Herzig, S., and Krijgsvel, J. (2012). Selective
486 enrichment of newly synthesized proteins for quantitative secretome analysis. *Nat. Biotechnol.*
487 **30**, 984–990.

488 Forester, C.M., Zhao, Q., Phillips, N.J., Urisman, A., Chalkley, R.J., Oses-Prieto, J.A., Zhang,
489 L., Ruggero, D., and Burlingame, A.L. (2018). Revealing nascent proteomics in signaling
490 pathways and cell differentiation. *Proc. Natl. Acad. Sci. U. S. A.* **115**, 2353–2358.

491 Frese, C.K., Mikhaylova, M., Stucchi, R., Gautier, V., Liu, Q., Mohammed, S., Heck, A.J.R.,
492 Altelaar, A.F.M., and Hoogenraad, C.C. (2017). Quantitative Map of Proteome Dynamics during
493 Neuronal Differentiation. *Cell Rep.* **18**, 1527–1542.

494 Gandin, V., Masvidal, L., Cargnello, M., Gyen, L., McLaughlan, S., Cai, Y., Tenkerian, C.,
495 Morita, M., Balanathan, P., Jean-Jean, O., et al. (2016). mTORC1 and CK2 coordinate ternary
496 and eIF4F complex assembly. *Nat. Commun.* **7**, 11127.

497 Hansen, B.K., Gupta, R., Baldus, L., Lyon, D., Narita, T., Lammers, M., Choudhary, C., and
498 Weinert, B.T. (2019). Analysis of human acetylation stoichiometry defines mechanistic
499 constraints on protein regulation. *Nat. Commun.* **10**, 1055.

500 Helbig, A.O., Gauci, S., Rajmakers, R., van Breukelen, B., Slijper, M., Mohammed, S., and
501 Heck, A.J.R. (2010). Profiling of N-acetylated protein termini provides in-depth insights into the
502 N-terminal nature of the proteome. *Mol. Cell. Proteomics* **9**, 928–939.

503 Howden, A.J.M., Geoghegan, V., Katsch, K., Efsthio, G., Bhushan, B., Boutureira, O.,
504 Thomas, B., Trudgian, D.C., Kessler, B.M., Dieterich, D.C., et al. (2013). QuaNCAT: quantitating
505 proteome dynamics in primary cells. *Nat. Methods* **10**, 343–346.

506 Hsieh, A.C., Liu, Y., Edlind, M.P., Ingolia, N.T., Janes, M.R., Sher, A., Shi, E.Y., Stumpf, C.R.,
507 Christensen, C., Bonham, M.J., et al. (2012). The translational landscape of mTOR signalling
508 steers cancer initiation and metastasis. *Nature* **485**, 55–61.

509 Huang, Y., Zhang, Q., Yang, L., Lin, L., Xie, J., Yao, J., Zhou, X., Zhang, L., Shen, H., and
510 Yang, P. (2021). Puromycin-Modified Silica Microsphere-Based Nascent Proteomics Method for
511 Rapid and Deep Nascent Proteome Profile. *Anal. Chem.* **93**, 6403–6413.

512 Kamenova, I., Mukherjee, P., Conic, S., Mueller, F., El-Saafin, F., Bardot, P., Garnier, J.-M.,
513 Dembele, D., Capponi, S., Timmers, H.T.M., et al. (2019). Co-translational assembly of
514 mammalian nuclear multisubunit complexes. *Nat. Commun.* **10**, 1740.

515 Keshwani, M.M., Klammt, C., von Daake, S., Ma, Y., Kornev, A.P., Choe, S., Insel, P.A., and
516 Taylor, S.S. (2012). Cotranslational cis-phosphorylation of the COOH-terminal tail is a key
517 priming step in the maturation of cAMP-dependent protein kinase. *Proc. Natl. Acad. Sci. U. S. A.*
518 **109**, E1221–E1229.

519 Kii, I., Sumida, Y., Goto, T., Sonamoto, R., Okuno, Y., Yoshida, S., Kato-Sumida, T., Koike, Y.,
520 Abe, M., Nonaka, Y., et al. (2016). Selective inhibition of the kinase DYRK1A by targeting its

521 folding process. *Nat. Commun.* 7, 11391.

522 Klann, K., Tascher, G., and Münch, C. (2020). Functional Translatome Proteomics Reveal
523 Converging and Dose-Dependent Regulation by mTORC1 and eIF2 α . *Mol. Cell* 77, 913–
524 925.e4.

525 Lai, Z.W., Petrera, A., and Schilling, O. (2015). Protein amino-terminal modifications and
526 proteomic approaches for N-terminal profiling. *Curr. Opin. Chem. Biol.* 24, 71–79.

527 Lamper, A.M., Fleming, R.H., Ladd, K.M., and Lee, A.S.Y. (2020). A phosphorylation-regulated
528 eIF3d translation switch mediates cellular adaptation to metabolic stress. *Science* 370, 853–
529 856.

530 Marciano, R., Leprivier, G., and Rotblat, B. (2018). Puromycin labeling does not allow protein
531 synthesis to be measured in energy-starved cells. *Cell Death Dis.* 9, 1–3.

532 McShane, E., Sin, C., Zauber, H., Wells, J.N., Donnelly, N., Wang, X., Hou, J., Chen, W.,
533 Storchova, Z., Marsh, J.A., et al. (2016). Kinetic Analysis of Protein Stability Reveals Age-
534 Dependent Degradation. *Cell* 167, 803–815.e21.

535 Mellacheruvu, D., Wright, Z., Couzens, A.L., Lambert, J.-P., St-Denis, N.A., Li, T., Miteva, Y.V.,
536 Hauri, S., Sardi, M.E., Low, T.Y., et al. (2013). The CRAPome: a contaminant repository for
537 affinity purification-mass spectrometry data. *Nat. Methods* 10, 730–736.

538 Mollapour, M., and Neckers, L. (2012). Post-translational modifications of Hsp90 and their
539 contributions to chaperone regulation. *Biochim. Biophys. Acta* 1823, 648–655.

540 Mueller, F., Friese, A., Pathe, C., da Silva, R.C., Rodriguez, K.B., Musacchio, A., and Bange, T.
541 (2021). Overlap of NatA and IAP substrates implicates N-terminal acetylation in protein
542 stabilization. *Sci Adv* 7.

543 Pankow, S., Bamberger, C., and Yates, J.R., 3rd (2019). A posttranslational modification code
544 for CFTR maturation is altered in cystic fibrosis. *Sci. Signal.* 12.

545 Parsons, J.L., Dianova, I.I., Finch, D., Tait, P.S., Ström, C.E., Helleday, T., and Dianov, G.L.
546 (2010). XRCC1 phosphorylation by CK2 is required for its stability and efficient DNA repair.
547 *DNA Repair* 9, 835–841.

548 Pisareva, V.P., Skabkin, M.A., Hellen, C.U.T., Pestova, T.V., and Pisarev, A.V. (2011).
549 Dissociation by Pelota, Hbs1 and ABCE1 of mammalian vacant 80S ribosomes and stalled
550 elongation complexes. *EMBO J.* 30, 1804–1817.

551 Reineke, L.C., Tsai, W.-C., Jain, A., Kaelber, J.T., Jung, S.Y., and Lloyd, R.E. (2017). Casein
552 Kinase 2 Is Linked to Stress Granule Dynamics through Phosphorylation of the Stress Granule
553 Nucleating Protein G3BP1. *Mol. Cell. Biol.* 37.

554 Schwanhäusser, B., Gossen, M., Dittmar, G., and Selbach, M. (2009). Global analysis of cellular
555 protein translation by pulsed SILAC. *Proteomics* 9, 205–209.

556 Schwarz, A., and Beck, M. (2019). The Benefits of Cotranslational Assembly: A Structural
557 Perspective. *Trends Cell Biol.* 29, 791–803.

558 Siddiqui-Jain, A., Drygin, D., Streiner, N., Chua, P., Pierre, F., O'Brien, S.E., Bliesath, J., Omori,

559 M., Huser, N., Ho, C., et al. (2010). CX-4945, an orally bioavailable selective inhibitor of protein
560 kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.
561 *Cancer Res.* 70, 10288–10298.

562 Sugiyama, N., Imamura, H., and Ishihama, Y. (2019). Large-scale Discovery of Substrates of
563 the Human Kinome. *Sci. Rep.* 9, 10503.

564 Thoreen, C.C., Chantranupong, L., Keys, H.R., Wang, T., Gray, N.S., and Sabatini, D.M. (2012).
565 A unifying model for mTORC1-mediated regulation of mRNA translation. *Nature* 485, 109–113.

566 Timms, R.T., Zhang, Z., Rhee, D.Y., Harper, J.W., Koren, I., and Elledge, S.J. (2019). A glycine-
567 specific N-degron pathway mediates the quality control of protein -myristoylation. *Science* 365.

568 Tong, M., Suttapitugsakul, S., and Wu, R. (2020). Effective Method for Accurate and Sensitive
569 Quantitation of Rapid Changes of Newly Synthesized Proteins. *Anal. Chem.* 92, 10048–10057.

570 Uchiyama, J., Ishihama, Y., and Imami, K. (2020). Quantitative nascent proteome profiling by
571 dual pulse labeling with O-propargyl-puromycin and stable isotope labeled amino acids. *J.*
572 *Biochem.*

573 Varland, S., Osberg, C., and Arnesen, T. (2015). N-terminal modifications of cellular proteins:
574 The enzymes involved, their substrate specificities and biological effects. *Proteomics* 15, 2385–
575 2401.

576 Yeom, J., Ju, S., Choi, Y., Paek, E., and Lee, C. (2017). Comprehensive analysis of human
577 protein N-termini enables assessment of various protein forms. *Sci. Rep.* 7, 6599.

Figure 1

Fig. 1 Profiling elongating nascent polypeptide chains by pSNAP.

a, Principle of the enrichment of NPCs with the pSNAP. **b**, Schematic representation of pSNAP workflow. HeLa cells are pulse labeled for 2 hr with a combination of 10 μ M puromycin and heavy amino acids or with only medium-heavy amino acids. After IP of NPCs with anti-puromycin antibodies, NPCs are eluted with 0.15% TFA and digested into tryptic peptides. The resulting peptide sample is analyzed by LC/MS/MS. Heavy-to-medium (H/M) ratios represent the degree of enrichment of NPCs. **c**, Exemplary MS spectra for AAALFLNR (STIP1) obtained with (top) and without (bottom) enrichment. The isotope clusters of the L, M, and H peaks correspond to non-specific proteins from the pre-existing proteome pool and from the 'medium' -labeled proteins and 'heavy' -labeled NPCs, respectively. **d**, Multi-scatter plots of log₂ H/M ratios from three independent experiments. **e**, pSNAP can enrich NPCs. (top) The ribosome elongates an NPC from its N-terminal end to the C-terminal end. Thus, positions of NPC-derived tryptic peptides are biased towards the N-termini of proteins. (bottom) Relative starting positions of identified peptides within proteins. The bars represent averaged values from three independent experiments.

Figure 2

Fig. 2 Quantitative analysis of translational responses and co-translational phosphorylation.

a, Experimental design for global analysis of translational changes induced by a CK2 inhibitor silmitasertib (10 μ M). **b**, A histogram of log₂ fold changes [H/M (silmitasertib/DMSO) ratios] of protein synthesis induced by silmitasertib. Averaged H/M ratios based on proteins quantified in at least two of the three replicates are shown. Results from individual replicates are shown in Supplementary Fig. 3b. A subset of proteins whose mRNAs contain a TOP motif is shown in dark blue. CK2 substrates determined by an in vitro kinase reaction are shown in orange. All quantified proteins are shown in black. The dashed lines indicate median values of the three groups (all, TOP motif, and CK2 substrates). The p-value was computed using the two-sided Wilcoxon rank-sum test. **c**, Change of NPC and phosphorylation levels due to silmitasertib treatment versus DMSO treatment. The indicated phosphorylation sites of G3BP1, HSP90AA1 and HSP90AB1 are known CK2 substrates. Levels of the NPCs were quantified from NPC-derived unphosphorylated peptides. The bars represent averaged values from two or three replicates.

Figure 3

Fig. 3 Characterization of protein Nt-acetylation and phosphorylation on nascent proteins

a, Enrichment of Nt-acetylated peptides with SCX-based fractionation. The percentage of the number of protein Nt-acetylated peptides in all peptides identified in individual fractions is shown. The bars represent averaged values from three replicates. **b**, The amino acid frequency at the second residue next to iMet of acetylated protein N-termini based on the absence (pink) or presence (light green) of iMet. Only nascent proteins that showed H/M $>$ 2 in at least one of the three replicates were considered. For comparison, the human proteome from the SwissProt protein database is shown. The p-value was computed using Fisher's exact test. **c**, Representative MS/MS spectra of Ac-SETAPAEATATPAPVEK (left) and Ac-SETAPAEATATPAPVEKSPAK (right) from histone H1.5. The insets show representative MS spectra of corresponding peptides and demonstrate that the protein Nt-acetylation and adjacent phosphorylation occurred on nascent H1.5. **d**, The comparison of H-labeled peptide intensities from Nt-acetylated (red), Nt-acetylated and phosphorylated (orange), and Nt-unmodified (grey) forms. **e**, Stoichiometry (%) of protein Nt-acetylation estimated based on intensities of H-labeled peptides from Nt-acetylated and counterpart (unmodified) forms. The bars represent averaged values from two or three replicates. **f**, Experimental design for peptide-pulldown assays using three different peptide probes. Nt-unmodified, Nt-acetylated, or Nt-acetylated and phosphorylated biotinylated peptides corresponding to amino acid residues from 2 to 22 (SETAPAEATATPAPVEKSPAK) of H1.5 were conjugated to streptavidin agarose resins. Beads were incubated with HeLa cell lysate, and eluted for LC/MS/MS analysis. **g**, Volcano plots from the pulldown assays of Nt-free vs Nt-acetylated peptides (left) and Nt-acetylated vs Nt-acetylated and phosphorylated peptides (right) are shown.

a

a Mouse brain

a, Schematic representation of the pSNAP workflow. Mouse primary cortical neurons are pulse labeled with SNAP-25::mCherry and infected with the pSNAP virus. The virus expresses the SNAP-25::mCherry and the SNAP-25::mCherry is pulse labeled with SNAP-25::mCherry. The SNAP-25::mCherry is then pulse labeled with SNAP-25::mCherry and the SNAP-25::mCherry is then pulse labeled with SNAP-25::mCherry.

a. After IP of NPCs with anti-puromycin antibodies, NPCs are eluted with 0.15% TFA and digested into tryptic peptides. The resulting peptide sample is analyzed by LC/MS/MS. b. Multi-scatter plots of log2 H/M ratios from three independent experiments using mouse primary neurons. c. pSNAP can enrich NPCs from primary neurons. Relative starting positions of identified peptides within proteins for enriched (left) or input (right) samples. The bars represent averaged values from three independent experiments. d. Experimental design for the differential nascent proteome profiling of the mouse primary cultures between DIV 5 and 14. e. A volcano plot showing differential NPC levels between DIV 5 and 14. Log2 FC (H/M: DIV14/DIV5) and p-values are computed from three biological replicates (see method). f. Gene ontology enrichment analyses for the significantly regulated NPCs (log2 FC>0.5 and p<0.05).

Supplementary Fig. 3

Supplementary Fig. 3 Quantitative analysis of translational changes associated with CX-4945 treatment.

a, pSNAP can enrich NPCs from HeLa cells treated with DMSO or CX-4945. Relative starting positions of identified peptides (only M- or H-labeled) within proteins for NPC-enriched samples. The bars represent averaged values from three independent experiments. b, Histogram of log2 FCs [H/M (silmitasertib/DMSO) ratios] of protein synthesis induced by silmitasertib. Results from individual replicates are shown. A subset of proteins whose mRNAs contain a TOP motif is shown in light blue. All quantified proteins are shown in pink. The p values were computed using two-sided Wilcoxon rank-sum test.

Supplementary Fig. 4

Supplementary Fig. 4 Quantitative analysis of nascent protein N-terminal acetylation.

a, Multi-scatter plots of log2 H/M ratios from three independent experiments using HeLa cells treated with DMSO or CHX. b, pSNAP can enrich NPCs. Relative starting positions of identified peptides within proteins for enriched (left) or input (right) samples. The bars represent averaged values from three independent experiments.

Methods

HeLa cell culture and pulse labeling with puromycin and SILAC amino acids

HeLa cells (ATCC) were cultured in Dulbecco's modified eagle medium (DMEM) (FUJIFILM Wako) supplemented with 10% fetal bovine serum (FBS) (Thermo Fisher Scientific). Cells were grown to approximately 70–80% confluence and then used for experiments. For pulse labeling experiments, the cell culture medium was switched to arginine- and lysine-free DMEM (Thermo Fisher Scientific) supplemented with 10% FBS and 10 μ M puromycin (FUJIFILM Wako), either “heavy” amino acids [0.398 mM L-($^{13}\text{C}_6$, $^{15}\text{N}_4$)-arginine (Arg”10”) and 0.798 mM L-($^{13}\text{C}_6$, $^{15}\text{N}_2$)-lysine (Lys”8”)] or “medium” amino acids [0.398 mM L-($^{15}\text{N}_4$)-arginine (Arg”4”) and 0.798 mM L-(D₄)-lysine (Lys”4”)] (Cambridge Isotope Laboratories), and incubated for 2 hr as previously described elsewhere (Imami et al., 2010, 2018; Uchiyama et al., 2020). For the proof-of-concept experiment (related to **Fig. 1b**), HeLa cells were pulse-labeled with a combination of 10 μ M puromycin and ‘heavy’ amino acids (Arg’10’ and Lys’8’) for 2 hr, while as control, cells were treated with only ‘medium-heavy’ amino acids (Arg’4’ and Lys’4’) and puromycin was omitted. To examine the degradation of puromycylated NPCs during puromycin labeling (related to **Supplementary Fig. 1b**), HeLa cells were treated with 10 μ M puromycin and either DMSO, 10 μ M MG-132 (Chemscene) or 1 μ M bortezomib (FUJIFILM Wako) for 15 min, 30 min, 60 min and 120 min. In the silmitasertib experiment (related to **Fig. 2a**), HeLa cells were pre-incubated with either DMSO or a CK2 inhibitor silmitasertib (MedChemExpress) (10 μ M) for 10 min, and then pulse-labeled with puromycin for 2 hr in the presence of either DMSO (+‘medium-heavy’ amino acids) or 10 μ M silmitasertib (+‘heavy’ amino acids). For the protein Nt-acetylation profiling (related to **Fig. 3a**), HeLa cells were pulse-labeled with puromycin for 2 hr in the presence of either 100 μ g/mL CHX (FUJIFILM Wako) (+‘medium-heavy’ amino acids) or DMSO (+‘heavy’ amino acids). After pulse-labeling, cells were washed twice with ice-cold PBS and collected by centrifugation. Three independent experiments were performed in all proteomic studies. All cells were maintained in an incubator at 37°C under humidified 5% CO₂ in air.

Mouse primary cortex cultures and pulse labeling

Primary cultures of cortical neurons were prepared as described with a few modifications (Kaeche and Banker, 2006). In brief, cortices were dissected from postnatal day 0 (P0) mice. Cortical neurons were dissociated using neuron dissociation solutions (FUJIFILM Wako) and plated on 35 mm (DIV7 neuron pulse labeling) or 60 mm (DIV5 and DIV14 neuron pulse labelling) dishes

coated with poly-L-lysine (Merck) at a density of 1×10^5 and 2×10^5 cells/cm², respectively, in MEM (Thermo Fisher Scientific) supplemented with 10% horse serum (Thermo Fisher Scientific), 0.6% D-glucose (Merck), 1 mM sodium pyruvate (Nacalai Tesque) and 1% penicillin-streptomycin (Thermo Fisher Scientific). Three hours after plating, the media was replaced by growth media consisting of Neurobasal-A medium (Thermo Fisher Scientific) supplemented with B-27 supplement (Thermo Fisher Scientific), GlutaMAX (Thermo Fisher Scientific) and penicillin-streptomycin (Thermo Fisher Scientific). Neurons were maintained at 37°C in 5% CO₂ until experiments. For pulse labeling experiments at 7 days in vitro (related to **Supplementary Fig. 2**) and experiments to assess differential translations between 5 and 14 days in vitro (related to **Supplementary Fig. 2d**), the cell culture medium was switched to arginine- and lysine-free Neurobasal-A medium (Research Institute for the Functional Peptides) supplemented with B-27 supplement, GlutaMAX, penicillin-streptomycin and either “heavy” amino acids or “medium-heavy” amino acids, and processed as described above. After pulse labeling, cells were washed two times with ice-cold PBS and directly lysed by using lysis buffer [100 mM HEPES-NaOH (pH 7.5), 150 mM NaCl, 1% Nonidet P-40 (NP-40), 1% protease inhibitor cocktail (Merck)] and further centrifuged at 21,500 x g for 5 min at 4°C to get rid of the cell debris. The supernatant was further used for immunoprecipitation with anti-puromycin antibody for the detection of the NPCs.

ICR mice were purchased (Shimizu). This study was carried out in accordance with the Guide for the Care and Use of Laboratory Animals from the Society for Neuroscience and was authorized by the Animal Care and Use Committee of Kyoto University.

Immunoprecipitation of NPCs with anti-puromycin antibody

HeLa cell pellets were lysed with a buffer [100 mM HEPES-NaOH (pH 7.5), 150 mM NaCl, 1% Nonidet P-40 (NP-40), protease inhibitor cocktail (Merck)], and cell debris was removed by centrifugation (4°C, 16,000 x g, 30 min). The protein concentration was measured using a BCA assay (Thermo Fisher Scientific), and 250 µg (in 250 µL) protein per sample was used for the following IP. For the silmitasertib treatment experiments (related to **Fig. 2a**), 125 µg protein inputs from ‘medium-heavy’- and ‘heavy’-labeled cells were combined (total 250 µg proteins). 62.6 µg Dynabeads™ Protein G Magnetic Beads (Thermo Fisher Scientific) and 15 µg anti-puromycin antibody (clone 12D10, Merck Millipore) per IP experiment were mixed in PBS-0.02% Tween 20 (PBS-T) and incubated for 30 min at room temperature with rotation. The supernatant was removed and the beads were washed twice with a conjugation buffer (20 mM sodium phosphate

and 150 mM NaCl). To crosslink the beads and the antibodies, the beads were suspended in 5 mM bis(sulfosuccinimidyl)suberate, disodium salt (BS³, Wako FUJIFILM) in the conjugation buffer and incubated for 30 min at 37°C. To quench the reaction, 50 mM (final concentration) Tris-HCl pH 7.5 was added and incubation was continued for 15 min at room temperature. The antibody-conjugated beads were then rinsed with 0.02% PBS-T, PBS, and the lysis buffer. The antibody-conjugated beads were incubated with 250 µg protein input for 1 hr at 4°C with slow rotation. The supernatant was transferred to a new tube, and the beads were washed three times with PBS supplemented with 850 mM NaCl. Puromycylated NPCs were eluted from the beads with 100 µL 0.15% trifluoroacetic acid (TFA) (FUJIFILM Wako), and the elution was repeated once more. All TFA eluates were combined and dried in a SpeedVac (Thermo Fisher Scientific).

Protein digestion and SCX fractionation

The dried samples were resuspended with 100 mM Tris-HCl pH 9.0 containing 8 M urea. Proteins were reduced with 10 mM dithiothreitol (DTT) (FUJIFILM Wako) for 30 min at 37°C, followed by alkylation with 50 mM 2-iodoacetamide (IAA) (FUJIFILM Wako) for 30 min at room temperature in the dark. The samples were diluted to 2 M urea with 50 mM ammonium bicarbonate. The proteins were digested with 1 µg lysyl endopeptidase (LysC) (FUJIFILM Wako) and 1 µg trypsin (Promega) overnight at 37°C on a shaking incubator. The resulting peptides were acidified with 0.5% TFA (final concentration), and fractionated with a StageTip containing SDB-XC (upper) and SCX (bottom) Empore disk membranes (GL Sciences) (Adachi et al., 2016). Peptides were eluted from the tip sequentially using 1) 0.5% TFA and 30% acetonitrile (ACN) 2) 1% TFA and 30% ACN 3) 2% TFA and 30% ACN, 4) 3% TFA and 30% ACN 5) 3% TFA, 100 mM ammonium acetate and 30% ACN 6) 4% TFA, 500 mM ammonium acetate and 30% ACN, and 7) 500 mM ammonium acetate and 30% ACN. For protein Nt-acetylated profiling (related to **Fig. 3a**), flowthrough and wash [with 0.1% TFA and 80% ACN] fractions were combined and measured by LC/MS/MS. The sample solution was evaporated in a SpeedVac and the residue was resuspended in 0.5% TFA and 4% ACN.

Peptide pulldown assay

Synthetic peptides were purchased from Synpeptide, and peptide sequences used were as follows: SETAPAETATPAPVEKSPAKK-K(biotin), Ac-SETAPAETATPAPVEKSPAKK-K(biotin), and Ac-SETAPAETATPAPVEKpSPAKK-K(biotin). Synthetic peptides (60 nmol each) were

incubated with 18 μ L streptavidin agarose resins (high capacity streptavidin agarose, Thermo Fisher Scientific) per experiment for 2 hr at room temperature in 80 μ L of lysis buffer (1% NP-40, 150 mM NaCl, 25 mM Tris-HCl pH 7.5, and protease and phosphatase inhibitor cocktails). Synthetic peptides bound to agarose resins were incubated with HeLa cell lysate (300 μ g in 500 μ L lysis buffer) for 2 hr at 4°C. Resins were washed three times with 1 mL of lysis buffer, and proteins bound to resins were eluted with 60 μ L of elution buffer [12 mM sodium deoxycholate, 12 mM sodium N-lauroylsarcosinate, 5 mM DTT, 100 mM Tris-HCl pH 9.0]. Afterward, samples were transferred to new tubes and processed for LC/MS/MS analysis as described elsewhere (Masuda et al., 2008)

Mass spectrometry and data-acquisition

Nano-scale reversed-phase liquid chromatography coupled with tandem mass spectrometry (nanoLC/MS/MS) was performed by an Orbitrap Fusion Lumos mass spectrometer (Thermo Fisher Scientific), connected to a Thermo Ultimate 3000 RSLCnano pump and an HTC-PAL autosampler (CTC Analytics, Zwingen, Switzerland) equipped with a self-pulled analytical column (150 mm length $\times$ 100 μ m i.d.) (Ishihama et al., 2002) packed with ReproSil-Pur C18-AQ materials (3 μ m, Dr. Maisch GmbH, Ammerbuch, Germany). The mobile phases consisted of (A) 0.5% acetic acid and (B) 0.5% acetic acid and 80% ACN. Peptides were eluted from the analytical column at a flow rate of 500 nL/min with the following gradient: 5-10% B in 5 min, 10-40% B in 60 min, 40-99% B in 5 min, and 99% for 5 min. The Orbitrap Fusion Lumos instrument was operated in the data-dependent mode with a full scan in the Orbitrap followed by MS/MS scans for 3 sec using higher-energy collisional dissociation (HCD). The applied voltage for ionization was 2.4 kV. The full scans were performed with a resolution of 120,000, a target value of 4×10^5 ions, and a maximum injection time of 50 ms. The MS scan range was m/z 300–1,500. The MS/MS scans were performed with a 15,000 resolution, a 5×10^4 target value, and a 50 ms maximum injection time. The isolation window was set to 1.6, and the normalized HCD collision energy was 30. Dynamic exclusion was applied for 20 sec.

Processing of mass spectrometry data

All raw data files were analyzed and processed by MaxQuant (Cox and Mann, 2008) (v1.6.17.0 or v.1.6.2.10), and the database search was performed with Andromeda (Cox et al., 2011) against the SwissProt database (version 2020-10, 42,372 human protein entries) or mouse UniProt

database (version 2020-3, 55,462 protein entries) spiked with common contaminants and enzyme sequences. Search parameters included two missed cleavage sites and variable modifications such as L-(¹³C₆,¹⁵N₄)-arginine, L-(¹³C₆,¹⁵N₂)-lysine, L-(¹⁵N₄)-arginine, L-(D₄)-lysine, methionine oxidation, protein N-terminal acetylation and phosphorylation of tyrosine, serine and threonine (only for the silmitasertib experiment related to **Fig. 2** and Nt-acetylome experiment related to **Fig. 3**). Cysteine carbamidomethylation was set as a fixed modification. The peptide mass tolerance was 4.5 ppm, and the MS/MS tolerance was 20 ppm. The false discovery rate (FDR) was set to 1% at the peptide spectrum match (PSM) level and protein level. For the SILAC-based protein quantification, a minimum of one ratio count (unique peptide ion) was used for quantification, and the 're-quantify' and 'match between runs' functions were employed. Raw H/M ratios were used for quantification related to **Fig. 1**, **Fig. 3**, and **Supplementary Fig. 2b** while normalized H/M ratios were used for the differential analysis of NPC levels (related to **Fig. 2** and **Supplementary Fig. 2d**). For label-free quantification of peptide pulldown samples (related to **Figs. 3f, g**), a minimum of two ratio counts was used for quantification. Only proteins quantified in 2 out of the 3 replicates in at least one condition were used for further analysis, and missing values were imputed from a normal distribution of log₂ LFQ intensity using a default setting (width 0.3, down shift 1.8) in Perseus (Tyanova et al., 2016). Volcano plots were generated based on log₂ FC (x-axis) and -log₁₀ p-value from two-sided t-test (y-axis). The curve indicates a cut-off for differentially interacting proteins (FDR<0.05, s0: 0.8).

For the differential NPC analysis in mouse primary cortex cultures (related to **Supplementary Fig. 2e**), normalized H/M ratios were log₂ transformed and replicates were averaged when they were quantified in at least two of the three replicates. Two-sided one sample t-tests were performed on the experimental data using Perseus (Tyanova et al., 2016) and proteins were considered as 'significantly regulated' when they were below a t-test p-value of 0.05 and above 0.5 (a log₂ ratio). GO enrichment (**Supplementary Fig. 2f**) of the significantly regulated proteins were performed using Metascape (Zhou et al., 2019).

Analysis of the positions of identified peptides within protein sequences

To calculate the positions of identified peptides within protein sequences (related to **Fig. 1e**, **Supplementary Fig. 2c**, and **Supplementary Fig. 4b**), we classified peptides into two groups based on their H/M ratios; H/M ≥ 2 (i.e., NPCs) and H/M < 2 (i.e., potential contaminants). The first amino acids within peptides were mapped onto a protein sequence, and their relative positions

within proteins (from N-term: 0 to C-term: 1) were calculated. For the input samples, all identified peptides were used to compute the positions within proteins. Only M- and H-labeled peptides were considered to calculate the positions within protein sequences in **Supplementary Fig. 3a**.

Western blotting

The cell lysates (corresponding to 28 µg protein) were re-suspended in LiDS loading sample buffer (Thermo Fisher Scientific) with 50 mM DTT and incubated at 70°C for 5 min. The protein samples were loaded onto a 4–12% gradient SDS-polyacrylamide gel (Thermo Fisher Scientific) and separated using electrophoresis. The proteins were then transferred to a PVDF membrane (Merck Millipore) using a semi-dry western blot transfer system set to a constant current of 200 mA for 30 min. The membranes were first blocked by incubation in 5% (w/v) BSA or 5% (w/v) skim milk in Tris-buffered saline and 0.1% tween 20 (TBS-T) and then incubated with anti-puromycin antibody (clone 3RH11, Cosmo Bio Co.) diluted 1:5,000, overnight at room temperature. The membrane was washed three times with 0.1% TBS-T, incubated with HRP-conjugated anti-mouse secondary antibody (1: 20,000 dilution) in 0.1% TBS-T 1 hr at room temperature, washed three times in TBS-T, and developed with ECL reagent (Thermo Fisher Scientific). Ubiquitinated proteins were detected using anti-ubiquitin rabbit antibody (CST) (1: 2,000 dilution) and HRP-conjugated anti-rabbit secondary antibody (1: 10,000 dilution). Chemiluminescence was detected using the luminescent image analyzer ImageQuant LAS-500 (Cytiva).

References

- Adachi, J., Hashiguchi, K., Nagano, M., Sato, M., Sato, A., Fukamizu, K., Ishihama, Y., and Tomonaga, T. (2016). Improved Proteome and Phosphoproteome Analysis on a Cation Exchanger by a Combined Acid and Salt Gradient. *Anal. Chem.* 88, 7899–7903.
- Cox, J., and Mann, M. (2008). MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. *Nat. Biotechnol.* 26, 1367–1372.
- Cox, J., Neuhauser, N., Michalski, A., Scheltema, R.A., Olsen, J.V., and Mann, M. (2011). Andromeda: a peptide search engine integrated into the MaxQuant environment. *J. Proteome Res.* 10, 1794–1805.
- Imami, K., Sugiyama, N., Tomita, M., and Ishihama, Y. (2010). Quantitative proteome and phosphoproteome analyses of cultured cells based on SILAC labeling without requirement of

206 serum dialysis. *Mol. Biosyst.* **6**, 594–602.

207 Imami, K., Milek, M., Bogdanow, B., Yasuda, T., Kastelic, N., Zauber, H., Ishihama, Y.,
 208 Landthaler, M., and Selbach, M. (2018). Phosphorylation of the Ribosomal Protein RPL12/uL11
 209 Affects Translation during Mitosis. *Mol. Cell* **72**, 84–98.e9.

210 Ishihama, Y., Rappsilber, J., Andersen, J.S., and Mann, M. (2002). Microcolumns with self-
 211 assembled particle frits for proteomics. *J. Chromatogr. A* **979**, 233–239.

212 Kaech, S., and Banker, G. (2006). Culturing hippocampal neurons. *Nat. Protoc.* **1**, 2406–2415.

213 Masuda, T., Tomita, M., and Ishihama, Y. (2008). Phase transfer surfactant-aided trypsin
 214 digestion for membrane proteome analysis. *J. Proteome Res.* **7**, 731–740.

215 Moriya, Y., Kawano, S., Okuda, S., Watanabe, Y., Matsumoto, M., Takami, T., Kobayashi, D.,
 216 Yamanouchi, Y., Araki, N., Yoshizawa, A.C., et al. (2019). The jPOST environment: an
 217 integrated proteomics data repository and database. *Nucleic Acids Res.* **47**, D1218–D1224.

218 Okuda, S., Watanabe, Y., Moriya, Y., Kawano, S., Yamamoto, T., Matsumoto, M., Takami, T.,
 219 Kobayashi, D., Araki, N., Yoshizawa, A.C., et al. (2017). jPOSTrepo: an international standard
 220 data repository for proteomes. *Nucleic Acids Res.* **45**, D1107–D1111.

221 Tyanova, S., Temu, T., Sinitcyn, P., Carlson, A., Hein, M.Y., Geiger, T., Mann, M., and Cox, J.
 222 (2016). The Perseus computational platform for comprehensive analysis of (prote)omics data.
 223 *Nat. Methods* **13**, 731–740.

224 Uchiyama, J., Ishihama, Y., and Imami, K. (2020). Quantitative nascent proteome profiling by
 225 dual pulse labeling with O-propargyl-puromycin and stable isotope labeled amino acids. *J.*
 226 *Biochem.*

227 Zhou, Y., Zhou, B., Pache, L., Chang, M., Khodabakhshi, A.H., Tanaseichuk, O., Benner, C.,
 228 and Chanda, S.K. (2019). Metascape provides a biologist-oriented resource for the analysis of
 229 systems-level datasets. *Nat. Commun.* **10**, 1523.